Treatment of brain oligometastases with hypofractionated stereotactic radiotherapy utilising volumetric modulated arc therapy

详细信息    查看全文

• 作者：Jeremy Croker ; Benjamin Chua ; Anne Bernard…
• 关键词：Stereotactic radiosurgery ; Brain metastasis ; Volumetric Modulated Arc Therapy ; VMAT ; Hypofractionation ; Local control
• 刊名：Clinical & Experimental Metastasis
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：33
• 期：2
• 页码：125-132
• 全文大小：615 KB
• 参考文献：1.Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary J-P (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363(9422):1665–1672CrossRef PubMed
  2.Minniti G, D’Angelillo RM, Scaringi C, Trodella LE, Clarke E, Matteucci P, Osti MF, Ramella S, Enrici RM, Trodella L (2014) Fractionated stereotactic radiosurgery for patients with brain metastases. J Neuro-Oncol 117(2):295–301CrossRef
  3.Jenkinson MD, Haylock B, Shenoy A, Husband D, Javadpour M (2011) Management of cerebral metastasis: evidence-based approach for surgery, stereotactic radiosurgery and radiotherapy. Eur J Cancer 47(5):649–655CrossRef PubMed
  4.Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, Gaspar LE, Sperduto PW, Vogelbaum MA, Radawski JD, Wang JZ (2012) Radiotherapeutic and surgical management for newly diagnosed brain metastasis (es): an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2(3):210–225PubMedCentral CrossRef PubMed
  5.Ogura K, Mizowaki T, Ogura M, Sakanaka K, Arakawa Y, Miyamoto S, Hiraoka M (2012) Outcomes of hypofractionated stereotactic radiotherapy for metastatic brain tumors with high risk factors. J Neuro-Oncol 109(2):425–432CrossRef
  6.Do L, Pezner R, Radany E, Liu A, Staud C, Badie B (2009) Resection followed by stereotactic radiosurgery to resection cavity for intracranial metastases. Int J Radiat Oncol* Biol* Phys 73(2):486–491CrossRef
  7.Gavrilovic IT, Posner JB (2005) Brain metastases: epidemiology and pathophysiology. J Neuro-Oncol 75(1):5–14CrossRef
  8.Linskey ME, Andrews DW, Asher AL, Burri SH, Kondziolka D, Robinson PD, Ammirati M, Cobbs CS, Gaspar LE, Loeffler JS (2010) The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncol 96(1):45–68CrossRef
  9.Connolly EP, Mathew M, Tam M, King JV, Kunnakkat SD, Parker EC, Golfinos JG, Gruber ML, Narayana A (2013) Involved field radiation therapy after surgical resection of solitary brain metastases—mature results. Neuro-oncology 328
  10.Nieder C, Grosu AL, Gaspar LE (2014) Stereotactic radiosurgery (SRS) for brain metastases: a systematic review. Radiat Oncol 9(155):717X–719
  11.Ahmed KA, Freilich JM, Abuodeh Y, Figura N, Patel N, Sarangkasiri S, Chinnaiyan P, Yu H-HM, Etame AB, Rao NG (2014) Fractionated stereotactic radiotherapy to the post-operative cavity for radioresistant and radiosensitive brain metastases. J Neuro-Oncol 118(1):179–186CrossRef
  12.Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol* Biol* Phys 37(4):745–751CrossRef
  13.Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann R-D, Carrie C (2011) Adjuvant whole
  ain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 29(2):134–141PubMedCentral CrossRef PubMed
  14.Mehta MP, Tsao MN, Whelan TJ, Morris DE, Hayman JA, Flickinger JC, Mills M, Rogers CL, Souhami L (2005) The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol* Biol* Phys 63(1):37–46CrossRef
  15.Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole
  ain irradiation: a randomised controlled trial. Lancet Oncol 10(11):1037–1044CrossRef PubMed
  16.Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H (2006) Stereotactic radiosurgery plus whole
  ain radiation therapy versus stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295(21):2483–2491CrossRef PubMed
  17.Ammirati M, Kshettry VR, Lamki T, Wei L, Grecula JC (2014) A prospective phase II trial of fractionated stereotactic intensity modulated radiotherapy with or without surgery in the treatment of patients with 1 to 3 newly diagnosed symptomatic brain metastases. Neurosurgery 74(6):586–594CrossRef PubMed
  18.Rajakesari S, Arvold ND, Jimenez RB, Christianson LW, Horvath MC, Claus EB, Golby AJ, Johnson MD, Dunn IF, Lee EQ (2014) Local control after fractionated stereotactic radiation therapy for brain metastases. J Neuro-Oncol 120(2):339–346CrossRef
  19.Kilburn JM, Ellis TL, Lovato JF, Urbanic JJ, Bourland JD, Munley MT, McMullen KP, Shaw EG, Tatter SB, Chan MD (2014) Local control and toxicity outcomes in brainstem metastases treated with single fraction radiosurgery: is there a volume threshold for toxicity? J Neuro-Oncol 117(1):167–174CrossRef
  20.Leeman JE, Clump DA, Wegner RE, Heron DE, Burton SA, Mintz AH (2012) Prescription dose and fractionation predict improved survival after stereotactic radiotherapy for brainstem metastases. Radiat Oncol 7(1):107PubMedCentral CrossRef PubMed
  21.Muacevic A, Kreth F, Mack A, Tonn J, Wowra B (2004) Stereotactic radiosurgery without radiation therapy providing high local tumor control of multiple brain metastases from renal cell carcinoma. Minim Invasive Neurosurg 47(4):203–208CrossRef PubMed
  22.Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC (1999) Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol* Biol* Phys 45(2):427–434CrossRef
  23.Vuong DA, Rades D, van Eck AT, Horstmann GA, Busse R (2013) Comparing the cost-effectiveness of two brain metastasis treatment modalities from a payer’s perspective: stereotactic radiosurgery versus surgical resection. Clin Neurol Neurosurg 115(3):276–284CrossRef PubMed
  24.Mayo CS, Ding L, Addesa A, Kadish S, Fitzgerald T, Moser R (2010) Initial experience with volumetric IMRT (RapidArc) for intracranial stereotactic radiosurgery. Int J Radiat Oncol* Biol* Phys 78(5):1457–1466CrossRef
  25.Andrevska A, Knight KA, Sale CA (2014) The feasibility and benefits of using volumetric arc therapy in patients with brain metastases: a systematic review. J Med Radiat Sci 61(4):267–276PubMedCentral CrossRef PubMed
  26.Awad R, Fogarty G, Hong A, Kelly P, Ng D, Santos D, Haydu L (2013) Hippocampal avoidance with volumetric modulated arc therapy in melanoma brain metastases—the first Australian experience. Radiat Oncol (London, England) 8:62. doi:10.​1186/​1748-717X-8-62 CrossRef
  27.Ma Y, Li M, Yin Y, Kong L, Sun X, Lin X, Yu J (2010) Hypofractionated stereotactic radiotherapy for brain metastases: a dosimetric and treatment efficiency comparison between volumetric modulated arc therapy and intensity modulated radiotherapy. Technol Cancer Res Treat 9(5):499–507CrossRef PubMed
  28.Ruschin M, Lee Y, Beachey D, Yeboah C, Wronski M, Babic S, Lochray F, Nico A, Khan L, Soliman H, Sahgal A (2015) Investigation of dose falloff for intact brain metastases and surgical cavities using hypofractionated volumetric modulated arc radiotherapy. Technol Cancer Res Treat. doi:10.​1177/​1533034614567277​ PubMedCentral
  29.Salkeld AL, Unicomb K, Hayden AJ, Van Tilburg K, Yau S, Tiver K (2014) Dosimetric comparison of volumetric modulated arc therapy and linear accelerator-based radiosurgery for the treatment of one to four brain metastases. J Med Imaging Radiat Oncol 58(6):722–728. doi:10.​1111/​1754-9485.​12188 CrossRef PubMed
  30.Broemme J, Abu-Isa J, Kottke R, Beck J, Wiest R, Malthaner M, Schmidhalter D, Raabe A, Aebersold D, Pica A (2013) Adjuvant therapy after resection of brain metastases. Strahlenther Onkol 189(9):765–770CrossRef PubMed
  31.Sanghavi SN, Miranpuri SS, Chappell R, Buatti JM, Sneed PK, Suh JH, Regine WF, Weltman E, King VJ, Goetsch SJ (2001) Radiosurgery for patients with brain metastases: a multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. Int J Radiat Oncol* Biol* Phys 51(2):426–434CrossRef
  32.Rodrigues G, Zindler J, Warner A, Lagerwaard F (2013) Recursive partitioning analysis for the prediction of stereotactic radiosurgery brain metastases lesion control. Oncologist 18(3):330–335PubMedCentral CrossRef PubMed
  33.Ling DC, Vargo JA, Wegner RE, Flickinger JC, Burton SA, Engh J, Amankulor N, Quinn AE, Ozhasoglu C, Heron DE (2015) Postoperative stereotactic radiosurgery to the resection cavity for large brain metastases: clinical outcomes, predictors of intracranial failure, and implications for optimal patient selection. Neurosurgery 76(2):150–157CrossRef PubMed
  34.Strauss I, Corn BW, Krishna V, Shahar T, Matceyevsky D, Gez E, Shtraus N, Ram Z, Kanner AA (2015) Patterns of failure after stereotactic radiosurgery of the resection cavity following surgical removal of brain metastases. World Neurosurg. doi:10.​1016/​j.​wneu.​2015.​07.​073 PubMed
  35.Wiggenraad R, Verbeek-de Kanter A, Kal HB, Taphoorn M, Vissers T, Struikmans H (2011) Dose–effect relation in stereotactic radiotherapy for brain metastases. Syst Rev. Radiother Oncol 98(3):292–297CrossRef
  36.Märtens B, Janssen S, Werner M, Frühauf J, Christiansen H, Bremer M, Steinmann D (2012) Hypofractionated stereotactic radiotherapy of limited brain metastases: a single-centre individualized treatment approach. BMC Cancer 12(1):497PubMedCentral CrossRef PubMed
  
• 作者单位：Jeremy Croker (1) (2)
  Benjamin Chua (2) (3)
  Anne Bernard (4)
  Maryse Allon (5)
  Matthew Foote (2) (5)
  
  1. Department of Radiation Oncology, Comprehensive Cancer Centre, Sir Charles Gairdner Hospital, Gairdner Drive, Nedlands, WA, 6009, Australia
  2. School of Medicine, The University of Queensland, 288 Herston Road, Herston, QLD, 4006, Australia
  3. Department of Radiation Oncology, Cancer Care Services, Royal Brisbane and Women’s Hospital, Joyce Tweddell Building, Herston, QLD, 4029, Australia
  4. QFAB Bioinformatics, Institute for Molecular Bioscience, Queensland Bioscience Precinct, The University of Queensland, 306 Carmody Road, St Lucia, QLD, 4072, Australia
  5. Department of Radiation Oncology, Division of Cancer Services, Princess Alexandra Hospital, University of Queensland, 199 Ipswich Road, Woolloongabba, QLD, 4102, Australia
  
• 刊物主题：Cancer Research; Biomedicine general; Oncology; Hematology; Surgical Oncology;
• 出版者：Springer Netherlands
• ISSN：1573-7276

文摘

Stereotactic radiosurgery (SRS) is commonly used to treat brain metastases, particularly in the oligometastatic setting. This study analyses our initial experience in treating oligometastatic brain disease using Volumetric Modulated Arc Therapy (VMAT) to deliver hypofractionated stereotactic radiotherapy (HFSRT). Sixty-one patients were treated with HFSRT with a median dose of 24 Gy (range 22–40 Gy) in a median of three fractions (range 2–10 fractions). With a median follow-up of 23 months, the local control rate was 74 % for the entire cohort. Local control was 87 % for patients who had surgery with no radiological evidence of residual disease followed by HFSRT compared with 69 % in patients treated with HFSRT alone. The overall median time post radiotherapy to local failure was 8.6 months and to extracranial failure was 7.9 months. The mean time to distant brain failure was 9.9 months. Twenty-two patients (36 %) died during the study with median time to death of 4.4 months. Median overall survival (OS) from treatment was 21 months and 12 month OS was 60 %. Our experience with HFSRT using VMAT for oligometastatic brain metastases in the post-operative setting demonstrates comparable local control and survival rates compared with international published data. In the intact brain metastasis setting, local control using the dose levels and delivery in this cohort may be inferior to radio-surgical series. Local control is independent of histology. Careful selection of patients remains critical.